Administration of an anti-IL-6 antibody was able to counteract this increased IL-6 level, leading to an almost complete maintenance of body weight and food intake and preventing the induction of markers of muscle atrophy, despite a slight increase in tumor mass (Figure 5A–5C, Supplementary Figure 5). Here, IL6 is linked to neoplasm.